

Attorney Docket No. 5051-574CT

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Martin et al.

Serial No.: 10/802,644

Filed: March 17, 2004

For: *Blocking Peptide for Inflammatory Cell Secretion*

Confirmation No.: 3963

Art Unit: 1644

Examiner: Haddad

Date: July 11, 2006

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Attachment E

Robbins and Cotran (2005), Pathologic Basis of Disease, cover and page 727.

# Robbins and Cotran PATHOLOGIC BASIS OF DISEASE

2005

VINAY KUMAR, MBBS, MD, FRCPath

Alice Hodge and Arthur Baer Professor  
Chairman, Department of Pathology  
The University of Chicago, Pritzker School of Medicine  
Chicago, Illinois

ABUL K. ABBAS, MBBS

Chair, Department of Pathology  
University of California, San Francisco  
San Francisco, California

NELSON FAUSTO, MD

Chairman, Department of Pathology  
University of Washington School of Medicine  
Seattle, Washington

*With Illustrations by*  
JENNICA PERKINS, MS, MFA



Philadelphia

0-7216-0187-1

BEST AVAILABLE COPY




FIGURE 15-12 Comparison of a normal bronchiole with that in asthma. Note the accumulation of mucus in the lumen resulting from an increase in the number of secreting goblet cells in the mucosa and hypertrophy of bronchial mucus glands. In addition, there is intense chronic inflammation due to recruitment of eosinophils, macrophages, and other inflammatory cells. Basement membrane underlying bronchial epithelium is thickened, and there is hypertrophy and hyperplasia of smooth muscle cells.

- *Postinfectious conditions*, including necrotizing pneumonia caused by bacteria (*Mycobacterium tuberculosis*, *Staphylococcus aureus*, *Haemophilus influenzae*, *Pseudomonas*), viruses (adenovirus, influenza virus, HIV), and fungi (*Aspergillus* species)
- *Bronchial obstruction*, owing to tumor, foreign bodies, and occasionally mucus impaction, in which the bronchiectasis is localized to the obstructed lung segment
- Other conditions, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and post-transplantation (chronic lung rejection, and chronic graft-versus-host disease after bone marrow transplantation)

**Etiology and Pathogenesis.** *Obstruction and infection* are the major influences associated with bronchiectasis, and it is likely that both are necessary for the development of full-fledged lesions, although either may come first. After bronchial obstruction (e.g., by mucus impaction, tumors, or foreign bodies), normal clearing mechanisms are impaired, there is pooling of secretions distal to the obstruction, and there is inflammation of the airway. Conversely, severe infections of the bronchi lead to inflammation, often with necrosis, fibrosis, and eventually dilatation of airways.

These mechanisms—infection and obstruction—are most readily apparent in the severe form of bronchiectasis associated with cystic fibrosis (Chapter 10). In this disorder, the primary defect in chloride transport leads to impaired secretion of chloride ions into mucus, low sodium and water content, defective mucociliary action, and accumulation of thick viscid secretions that obstruct the airways. This leads to